Humana (HUM) Cash & Equivalents (2009 - 2026)

Humana (HUM) has 18 years of Cash & Equivalents data on file, last reported at $5.0 billion in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 16.49% year-over-year to $5.0 billion in Q1 2026; TTM through Mar 2026 was $5.0 billion, a 16.49% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, up 89.1% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.0 billion, up from $4.2 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for HUM reached as high as $16.2 billion in Q2 2023 and fell as low as $2.2 billion in Q4 2024.
• Historically, Cash & Equivalents has averaged $7.1 billion across 5 years, with a median of $5.1 billion in 2024.
• Across the five-year window, Cash & Equivalents soared 215.01% in 2022 and plunged 66.23% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $5.1 billion in 2022, then dropped by 7.25% to $4.7 billion in 2023, then slumped by 52.68% to $2.2 billion in 2024, then surged by 89.1% to $4.2 billion in 2025, then advanced by 17.88% to $5.0 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $5.0 billion in Q1 2026, $4.2 billion in Q4 2025, and $5.4 billion in Q3 2025.